Brought to you by 
Lilly and Sanofi collaborate on colon cancer treatment
08 Mar 2004
Executive Summary
Eli Lilly and Sanofi will collaborate in the US to register, develop, and market Eloxatin (oxaliplatin), Sanofi's new platinum- based treatment for use in combination with 5-FU for all forms of advanced metastatic colorectal cancer. Sanofi has rights to the drug under license from Debiopharm SA.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly and Sanofi collaborate on colon cancer treatment
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice